Back to top
more

CVRx (CVRX)

(Delayed Data from NSDQ)

$9.22 USD

9.22
551,963

+0.74 (8.73%)

Updated May 3, 2024 04:00 PM ET

After-Market: $9.21 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

New Strong Buy Stocks for January 30th

HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'

CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Boeing, McDonald's, Monster Beverage in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why 'Trend' Investors Would Love Betting on CVRx (CVRX)

CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know

Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?

Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.

Recent Price Trend in CVRx (CVRX) is Your Friend, Here's Why

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes CVRx (CVRX) a New Strong Buy Stock

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 24.56% and 6.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?

CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

How Much Upside is Left in CVRx (CVRX)? Wall Street Analysts Think 25.09%

The consensus price target hints at a 25.1% upside potential for CVRx (CVRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 3.51% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 7.27% and 5.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Stock Jumps 6%: Will It Continue to Soar?

Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.